Description
IMPLEMENTING EO 14398 DEI DISCRIMINATION
Base award description: NEW AWARD FOR TRIFLUOPERAZINE TABLETS WITH SANDOZ, INC. ORDERING PERIOD IS JANUARY 14, 2023 TO JANUARY 13, 2024 WITH FOUR ONE-YEAR OPTIONS.
First action · last action
2022-08-19 · 2026-08-31
Transactions
12
First transaction's obligation
$0
Base + all options value (sum of deltas)
$236,746
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
2
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 12 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2022-08-19+$0= $0
- Mod P000012022-12-20+$0= $0
- Mod P000022023-04-17+$0= $0
- Mod P000032023-11-30+$0= $0
- Mod P000042024-02-01+$0= $0
- Mod P000052024-02-15+$0= $0
- Mod P000062024-02-22+$0= $0
- Mod P000072024-12-17+$0= $0
- Mod P000082024-12-27+$0= $0
- Mod P000092025-11-20+$0= $0
- Mod P000102026-01-12+$0= $0
- Mod P000112026-08-31+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2022-08-19 | +$0 | $0 | NEW AWARD FOR TRIFLUOPERAZINE TABLETS WITH SANDOZ, INC. ORDERING PERIOD IS JANUARY 14, 2023 TO JANUARY 13, 202… |
| Mod P00001· ADD SUBCONTRACTING PLAN | 2022-12-20 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE SANDOZ INC. 2023 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF JA… |
| Mod P00002· OTHER ADMINISTRATIVE ACTION | 2023-04-17 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE THE DRUG SUPPLY CHAIN SECURITY ACT (DSCSA) LANGUAGE INTO THE CONTRA… |
| Mod P00003· EXERCISE AN OPTION | 2023-11-30 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO EXERCISE THE 1ST OPTION YEAR FOR TRIFLUOPERAZINE TABLETS UNDER CONTRACT 36E7972… |
| Mod P00004· ADD SUBCONTRACTING PLAN | 2024-02-01 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE SANDOZ INC. 2024 SUBCONTRACTING PLAN. |
| Mod P00005· OTHER ADMINISTRATIVE ACTION | 2024-02-15 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE A CHANGE IN THE ADMINISTRATION AND SALES POINT OF CONTACT FOR SANDO… |
| Mod P00006· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2024-02-22 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO UPDATE THE TERMS OF THE CRF PAYMENT REMITTAL AND SUBMISSION OF QUARTERLY SALES… |
| Mod P00007· EXERCISE AN OPTION | 2024-12-17 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO EXERCISE OPTION YEAR 2 FOR NC 36E79722D0033 WITH SANDOZ, INC. FOR THE PERIOD OF… |
| Mod P00008· ADD SUBCONTRACTING PLAN | 2024-12-27 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE SANDOZ INC. 2025 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF JA… |
| Mod P00009· EXERCISE AN OPTION | 2025-11-20 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO EXERCISE THE 3RD OPTION YEAR FOR TRIFLUOPERAZINE TABLETS UNDER CONTRACT 36E7972… |
| Mod P00010· ADD SUBCONTRACTING PLAN | 2026-01-12 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE SANDOZ INC. 2026 SUBCONTRACTING PLAN INTO NC 36E79722D0033. |
| Mod P00011· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2026-08-31 | +$0 | $0 | IMPLEMENTING EO 14398 DEI DISCRIMINATION |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI ETJGHMFH1MT5)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36F79723D0187 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79723D0005 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79723D0001 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79722D0016 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79722D0011 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79721D0010 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2021 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79722D0033_3600 · retrieved 2026-09-26.